GlassScriptPhysician profile
Moti L Tiku
NPI 1780758763
$4,332.40
in general payments reported to CMS, 2019-2025
20 companies · $662 in 2025
The $662 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $534 · 2021: $512 · 2022: $611 · 2023: $863 · 2024: $832 · 2025: $662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,342 · Education: $14.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,342.07 |
| Education | $14.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,309.18 | 2019-2024 | Enbrel, Otezla, Evenity |
| Abbvie INC. | $1,052.53 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $632.85 | 2019-2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $509.85 | 2020-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $309.59 | 2024-2025 | |
| Lilly USA, LLC | $135.61 | 2020-2024 | Taltz, Olumiant |
| Hikma Pharmaceuticals USA | $81.00 | 2019-2021 | |
| Horizon Therapeutics Plc | $57.54 | 2019-2020 | |
| Aurinia Pharma U.S., INC. | $44.01 | 2022-2025 | Lupkynis |
| Radius Health, INC. | $39.69 | 2020 | |
| Glaxosmithkline, LLC. | $28.17 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $17.85 | 2023 | |
| Mallinckrodt Hospital Products INC. | $16.71 | 2024 | Acthar |
| Octapharma USA, INC. | $15.11 | 2025 | Octagam Immune Globulin (Human) |
| Sebela Pharmaceuticals INC. | $14.95 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $14.26 | 2020 | |
| Celltrion USA INC. | $14.22 | 2023 | Yuflyma |
| Sandoz INC. | $13.86 | 2023 | Hyrimoz |
| Sobi, INC | $13.42 | 2024 | |
| Celgene Corporation | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moti Tiku listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.